Stay updated on Pembrolizumab in mHSPC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in mHSPC Clinical Trial page.

Latest updates to the Pembrolizumab in mHSPC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe study history now shows a new revision entry, changing the record from v3.6.6 to v3.7.0. This indicates the study record has been updated in its version history.SummaryDifference0.1%

- Check29 days agoChange DetectedNew sections such as Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Eligibility, Arms and Interventions, Study Description, and Study Status were added to the study record history on 2026-09-02. The 2025-10-01 entry was removed from the history.SummaryDifference1%

- Check36 days agoChange DetectedA new revision entry, Revision: v3.6.6, was added to the Study Record Versions list, replacing the previous Revision: v3.6.5. This indicates an updated version of the study record in the history.SummaryDifference0.1%

- Check57 days agoChange DetectedA new revision entry v3.6.5 was added to the record history, and the previous v3.6.4 entry was removed. This reflects a maintenance update to the page's version history rather than substantive changes to the study information or functionality.SummaryDifference0.1%

- Check71 days agoChange DetectedA new platform revision entry (v3.6.4) has been added, replacing the previous v3.6.3. This reflects a backend/UI update to the ClinicalTrials.gov interface rather than a change to the study data or records.SummaryDifference0.1%

- Check93 days agoChange DetectedA new latest revision entry (v3.6.3) is added to the history, replacing the previous v3.6.2 entry and signaling an update to the study record.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in mHSPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in mHSPC Clinical Trial page.